Navigation Links
Monarch Labs to Demonstrate Maggot Therapy at Diabetic Limb Salvage Conference
Date:9/22/2009

IRVINE, Calif., Sept. 22 /PRNewswire/ -- Monarch Labs LLC, the exclusive supplier of Medical Maggots(TM) in the United States, announced today that its Laboratory Director and co-founder, Dr. Ronald Sherman, will attend the Diabetic Limb Salvage conference in Washington, DC, from September 24 to September 26. At Monarch's table display, Dr. Sherman will exhibit the company's Medical Maggots(TM) product (disinfected Phaenicia sericata larvae) and demonstrate this natural therapy to meeting participants.

Maggot therapy is the intentional introduction of live, disinfected maggots (fly larvae) into non-healing human and animal wounds for the purposes of selectively cleaning out only the dead tissue in the wounds to allow healing. Medical Maggots(TM) were cleared for marketing by the U.S. Food and Drug Administration in 2004, and since that time this method of treating non-healing wounds has steadily increased.

"Maggot therapy represents a revolutionary, natural and cost-effective medical device for cleaning many types of wounds," Sherman said. "In regular use in over 20 countries around the world, it has proven to be a safe and effective treatment. My goal in attending this conference is to educate more health care practitioners about the use of maggot therapy for their diabetic foot ulcer patients."

About 600,000 diabetics get foot ulcers every year nationwide, and traditional medical practices can cost up to $8,000 to treat such wounds, according to reports. Poor blood flow in the lower legs makes those ulcers difficult to heal.

Limb-salvage experts say many of the 80,000-plus amputations of toes, feet and lower legs that diabetics undergo each year in the U.S. are preventable, and that foot amputations alone can cost up to $30,000. Maggot therapy can be used for many types of diabetic foot ulcers. In recently published studies, nearly half of the wounds in diabetics scheduled for amputation were healed with maggot therapy, and amputation was avoided.

"When maggot therapy is used before the wounds progress to the point that amputation may be unavoidable, the success is even greater," Sherman said. "That is why we remind therapists not to hold off using maggot therapy as though it is a last resort. Patients shouldn't have to waste weeks, months or even years before they finally receive maggot therapy, all the while suffering from their chronic, limb-threatening wounds."

Medical Maggots(TM) also offer a much more cost-effective and natural way of treating these wounds. A vial of Medical Maggots(TM) sufficient for a single course of maggot therapy costs about $100 and the related dressings cost about $20. Most patients require no more than two or three treatments.

In addition, health care insurers are increasingly reimbursing patients who use maggot therapy. In September 2008, the American Medical Association, in collaboration with the Centers for Medicare and Medicaid Services, issued reimbursement coding guidelines for medicinal maggots and maggot therapy.

The Diabetic Limb Salvage conference, sponsored by Georgetown University Hospital/MedStar, will be held at the JW Marriott Pennsylvania Avenue in Washington, DC, from September 24 to 26. The education program, which is expected to attract 1,100 attendees, will be presented by more than 60 nationally known diabetic limb salvage experts.

About Medical Maggots(TM)

Medical Maggots(TM) (disinfected Phaenicia sericata larvae) are a proprietary strain of living fly larvae that are raised and processed in specialized facilities. They represent the first living organism ever allowed by the U.S. FDA for production and marketing as a prescription-only medical device. Medical Maggots(TM) are used for debriding non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers and non-healing traumatic or post surgical wounds.

About Monarch Labs

Monarch Labs is a life sciences company that researches, develops and commercializes innovative and proprietary wound care products. Monarch's lead product is Medical Maggots(TM), the only maggots allowed for marketing in the United States as a medical device. In March 2009, Monarch launched the first wound dressing in the U.S. specifically designed to make maggot therapy easier and quicker to administer. The dressing has been cleared by the FDA for manufacturing and marketing under the trade name LeFlap(TM). For more information, visit www.monarchlabs.com.


'/>"/>
SOURCE Monarch Labs LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hitachi Medical Systems and Monarch Medical Announced as Co- Title Sponsors of the Health Connect Partners 2009 Fall Radiology and Imaging Conference
2. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
3. MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
4. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation
5. TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
6. New type of sirolimus-eluting stent demonstrates superior results
7. Steelbox Demonstrates Open Video Framework with SRI International and Telindus Surveillance Solutions
8. PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009
9. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
10. Research Demonstrates that HerbalSciences Proprietary Elderberry Extract Prevents in Vitro H1N1 Influenza Infection
11. Sparta Systems Demonstrates Growth in Asia-Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: